Evidence map›Paper›PMID 35117041›Full record

ArticleTranslational cancer research2019

Plasma enhance drug sensitivity to bortezomib by inhibition of cyp1a1 in myeloma cells.

Dehui Xu, Qingjie Cui, Yujing Xu, Zeyu Chen, Wenjie Xia, Yanjie Yang, Dingxin Liu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. The Relationship ofJournal of clinical medicine · 2021
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Dehui XuState Key Laboratory of Electrical Insulation and Power Equipment, Centre for Plasma Biomedicine, First Affiliated Hospital of the Medical School, Xi'an Jiaotong University, Xi'an 710049, China.
Qingjie CuiThe School of Life Science and Technology, First Affiliated Hospital of the Medical School, Xi'an Jiaotong University, Xi'an 710049, China.
Yujing XuState Key Laboratory of Electrical Insulation and Power Equipment, Centre for Plasma Biomedicine, First Affiliated Hospital of the Medical School, Xi'an Jiaotong University, Xi'an 710049, China.
Zeyu ChenState Key Laboratory of Electrical Insulation and Power Equipment, Centre for Plasma Biomedicine, First Affiliated Hospital of the Medical School, Xi'an Jiaotong University, Xi'an 710049, China.
Wenjie XiaState Key Laboratory of Electrical Insulation and Power Equipment, Centre for Plasma Biomedicine, First Affiliated Hospital of the Medical School, Xi'an Jiaotong University, Xi'an 710049, China.
Yanjie YangDepartment of Cardiovascular Medicine, First Affiliated Hospital of the Medical School, Xi'an Jiaotong University, Xi'an 710049, China.
Dingxin LiuState Key Laboratory of Electrical Insulation and Power Equipment, Centre for Plasma Biomedicine, First Affiliated Hospital of the Medical School, Xi'an Jiaotong University, Xi'an 710049, China.
First Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDrug resistance is one of the major problems encountered in clinical therapy of multiple myeloma treatment. Combination treatment with several drugs may increase the sensitivity and overcome drug resistance.

methodsHere, we combined chemotherapy with a newly developed technology, cold atmospheric plasma, to enhance drug sensitivity.

resultsWe found that plasma treatment had a synergistic anti-cancer effect with a first line drug (bortezomib). Based on our previous study, we further found that plasma treatment could inhibit Notch pathway and down-regulate cyp1a1 expression and enzyme activity, which contributing to the enhanced drug sensitivity to bortezomib after combination of bortezomib with gas plasma.

conclusionsOur results showed a new strategy to overcome drug resistance by combination of traditional chemotherapy with cold atmospheric plasma.

Indexed as

Cold atmospheric plasmacyp1a1drug resistancemultiple myeloma (MM)notch

Identifiers

PMID35117041
PMCPMC8798238
OpenAlexW2995210142

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.